Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults

References

• Worldometer. COVID-19 coronavirus pandemic. 2019. [accessed 2022 Apr 1]. https://www.worldometers.info/coronavirus/
   Google Scholar
• The New York Times. Tracking Coronavirus Vaccinations Around the World. 2022. [accessed 2022 Apr 1]. https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html
   Google Scholar
• Mallapaty S, Callaway E, Kozlov M, Ledford H, Pickrell J, Noorden RV. How COVID vaccines shaped 2021 in eight powerful charts. Nature. 2021;600(7890):1–12. doi:10.1038/d41586-021-03686-x.
   Web of Science ®Google Scholar
• Liu Q, Qin C, Liu M, Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infect Dis Poverty. 2021;10(1):132. doi:10.1186/s40249-021-00915-3.
   PubMed Web of Science ®Google Scholar
• Garcia-Beltran WF, St Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, Berrios C, Ofoman O, Chang CC, Hauser BM, et al. mRNA-Based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022;185(3):457–466. doi:10.1016/j.cell.2021.12.033.
   PubMed Web of Science ®Google Scholar
• Pajon R, Doria-Rose NA, Shen X, Schmidt SD, O’-Dell S, McDanal C, Feng W, Tong J, Eaton A, Maglinao M, et al. SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination. N Engl J Med. 2022;386(11):1088–1091. doi:10.1056/NEJMc2119912.
   PubMed Web of Science ®Google Scholar
• Angkasekwinai N, Niyomnaitham S, Sewatanon J, Phumiamorn S, Sukapirom K, Senawong S, Mahasirimongkol S, Toh ZQ, Umrod P, Somporn T, et al. The immunogenicity and safety of different COVID-19 booster vaccination following CoronaVac or ChAdox1 nCov-19 primary series. medRxiv. 2022. doi:10.1101/2021.11.29.21266947.
   Google Scholar
• Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, Reis BY, Balicer RD. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093–2100. doi:10.1016/S0140-6736(21)02249-2.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211. doi:10.1038/s41591-021-01377-8.
   PubMed Web of Science ®Google Scholar
• ONE. The astoundingly unequal vaccine rollout. 2022. [accessed 2022 Apr 1]. https://www.one.org/africa/issues/covid-19-tracker/explore-vaccines/.
   Google Scholar
• Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, Cameron JC, Charlton S, Clutterbuck EA, Collins AM, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021;398(10303):856–869. doi:10.1016/S0140-6736(21)01694-9.
   PubMed Web of Science ®Google Scholar
• Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S, Abu-Omar A, Ziegler L, Guckelmus C, Urschel R, et al. Immunogenicity and reactogenicity of heterologous ChAdox1 nCov-19/mRNA vaccination. Nat Med. 2021;27(9):1530–1535. doi:10.1038/s41591-021-01464-w.
   PubMed Web of Science ®Google Scholar
• Yorsaeng R, Vichaiwattana P, Klinfueng S, Wongsrisang L, Sudhinaraset N, Vongpunsawad S, Poovorawan Y. Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria). medRxiv. 2021. doi:10.1101/2021.09.01.21262955.
   Google Scholar
• U.S. Department of Health and Human Services, Food and drug administration, center for biologics evaluation and research. Guidance for Industry Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. 2007. [accessed 2022 Apr 1]. https://www.fda.gov/media/73679/download
   Google Scholar
• Koonpaew S, Kaewborisuth C, Srisutthisamphan K, Wanitchang A, Thaweerattanasinp T, Saenboonrueng J, Poonsuk S, Jengarn J, Viriyakitkosol R, Kramyu J, et al. A single-cycle influenza a virus-based SARS-CoV-2 vaccine elicits potent immune responses in a mouse model. Vaccines (Basel). 2021;9(8):850. doi:10.3390/vaccines9080850.
   PubMed Web of Science ®Google Scholar
• Murugesan K, Jagannathan P, Pham TD, Pandey S, Bonilla HF, Jacobson K, Parsonnet J, Andrews JR, Weiskopf D, Sette A, et al. Interferon-γ release assay for accurate detection of severe acute respiratory syndrome coronavirus 2 T-Cell response. Clin Infect Dis. 2021;73(9):e3130–e3132. doi:10.1093/cid/ciaa1537.
   PubMedGoogle Scholar
• Martínez-Gallo M, Esperalba-Esquerra J, Pujol-Borrell R, Sandá V, Arrese-Muñoz I, Fernández-Naval C, Antón-Pagarolas A, Cardona V, Labrador-Horrillo M, Pumarola-Suñé T, et al. Commercialized kit to assess T-cell responses against SARS-CoV-2 S peptides. A pilot study in health care workers. medRxiv. 2021. doi:10.1101/2021.03.31.21254472.
   Google Scholar
• Angkasekwinai N, Sewatanon J, Niyomnaitham S, Phumiamorn S, Sukapirom K, Sapsutthipas S, Sirijatuphat R, Wittawatmongkol O, Senawong S, Mahasirimongkol S, et al. Safety and Immunogenicity of CoronaVac and ChAdox1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers [published online ahead of print, 2022 Mar 5]. Vaccine. X. doi:10.1016/j.jvacx.2022.100153
   Google Scholar
• Groß R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D, Erdemci-Evin S, Mayer B, Hoffmann M, Pöhlmann S, et al. Heterologous ChAdox1 nCov-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity. eBiomedicine. 2021;75:103761. doi:10.1016/j.ebiom.2021.103761.
   PubMed Web of Science ®Google Scholar
• Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Ramos GM, Dopfer-Jablonka A, Heidemann A, Ritter C, Friedrichsen M, et al. Humoral and cellular immune response against SARS-CoV-2 variants following heterologous and homologous ChAdox1 nCov-19/bnt162b2 vaccinationp. medRxiv. 2021. doi:10.1101/2021.06.01.21258172.
   Google Scholar
• Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J, Campins M, Portolés A, González-Pérez M, Morales MTG, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdox1-S-primed participants (CombiVacs): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021;398(10300):121–130. doi:10.1016/S0140-6736(21)01420-3.
   PubMed Web of Science ®Google Scholar
• Pozzetto B, Legros V, Djebali S, Barateau V, Guibert N, Villard M, Peyrot L, Allatif O, Fassier JB, Massardier-Pilonchéry A, et al. Immunogenicity and efficacy of heterologous ChAdox1–bnt162b2 vaccination. Nature. 2021;600(7890):701–706. doi:10.1038/s41586-021-04120-y.
   PubMed Web of Science ®Google Scholar
• Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385(7):585–594. doi:10.1056/NEJMoa2108891.
   PubMed Web of Science ®Google Scholar
• Vacharathit V, Aiewsakun P, Manopwisedjaroen S, Srisaowakarn C, Laopanupong T, Ludowyke N, Phuphuakrat A, Setthaudom C, Ekronarongchai S, Srichatrapimuk S, et al. CoronaVac induces lower neutralising activity against variants of concern than natural infection. Lancet Infect Dis. 2021;21(10):1352–1354. doi:10.1016/S1473-3099(21)00568-5.
   PubMed Web of Science ®Google Scholar
• Qahtani MA, Bhattacharyya S, Alawadi A, Mahmeed HA, Sayed JA, Justman J, El-Sadr WM, Hidary J, Mukherjee S. Morbidity and mortality from COVID-19 postvaccination breakthrough infections in association with vaccines and the emergence of variants in Bahrain. Res Sq. 2021. doi:10.21203/rs.3.rs-828021/v1.
   Google Scholar
• Angyal A, Longet S, Moore SC, Payne RP, Harding A, Tipton T, Rongkard P, Ali M, Hering LM, Meardon N, et al. T-Cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. The Lancet Microbe. 2022;3(1):E21–E31. doi:10.1016/S2666-5247(21)00275-5.
   PubMedGoogle Scholar
• Sritipsukho P, Khawcharoenporn T, Siribumrungwong B, Damronglerd P, Suwantarat N, Satdhabudha A, Chaiyakulsil C, Sinlapamongkolkul P, Tangsathapornpong A, Bunjoungmanee P, et al. Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study. Emerg Microbes Infect. 2022;11(1):585–592. doi:10.1080/22221751.2022.2037398.
   PubMed Web of Science ®Google Scholar
• Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, Olsha-Castell S, Arad D, Hasin T, Levi N, et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med. 2021;385(23):2140–2149. doi:10.1056/NEJMoa2109730.
   PubMed Web of Science ®Google Scholar
• Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation. 2021;144(6):471–484. doi:10.1161/CIRCULATIONAHA.121.056135.
   PubMed Web of Science ®Google Scholar
• Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, Miller J, Schrag SJ, Verani JR. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. Jama. 2022;327(7):639–651. doi:10.1001/jama.2022.0470.
   PubMed Web of Science ®Google Scholar
• Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, Lewis N, Natarajan K, Stenehjem E, Grannis SJ, et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19–associated Emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance — VISION network, 10 States, August 2021–January 2022. Mmwr. 2022;71(7):255–263. doi:10.15585/mmwr.mm7107e2.
   PubMed Web of Science ®Google Scholar
• Clemens SAC, Weckx L, Clemens R, Mendes AVA, Souza RA, Silveira MBV, da Guarda SNF, de Nobrega MM, de Moraes Pinto MI, Gonzalez IGS, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. The Lancet. 2022;399(10324):521–529. doi:10.1016/S0140-6736(22)00094-0.
   PubMed Web of Science ®Google Scholar
• Cheng SMS, Mok CKP, Leung YWY, Ng SS, Chan KCK, Ko FW, Chen C, Yiu K, Lam BHS, Lau EHY, et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat Med. 2022;28(3):486–489. doi:10.1038/s41591-022-01704-7.
   PubMed Web of Science ®Google Scholar
• Pérez-Then E, Lucas C, Monteiro VS, Miric M, Brache V, Cochon L, Vogels CBF, Malik AA, De la Cruz E, Jorge A, et al. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nat Med. 2022;28(3):481–485. doi:10.1038/s41591-022-01705-6.
   PubMed Web of Science ®Google Scholar